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Rift Valley fever virus (RVFV), a member of the Phlebovirus genus in the Bunyaviridae family, is transmitted by mosquitoes and infects both
humans and domestic animals, particularly cattle and sheep. Since primary RVFV strains must be handled in BSL-3+ or BSL-4 facilities, a RVFV
cell–cell fusion assay will facilitate the investigation of RVFV glycoprotein function under BSL-2 conditions. As for other members of the
Bunyaviridae family, RVFV glycoproteins are targeted to the Golgi, where the virus buds, and are not efficiently delivered to the cell surface.
However, overexpression of RVFV glycoproteins using an alphavirus replicon vector resulted in the expression of the glycoproteins on the surface
of multiple cell types. Brief treatment of RVFV glycoprotein expressing cells with mildly acidic media (pH 6.2 and below) resulted in rapid and
efficient syncytia formation, which we quantified by β-galactosidase α-complementation. Fusion was observed with several cell types, suggesting
that the receptor(s) for RVFV is widely expressed or that this acid-dependent virus does not require a specific receptor to mediate cell–cell fusion.
Fusion occurred over a broad temperature range, as expected for a virus with both mosquito and mammalian hosts. In contrast to cell fusion
mediated by the VSV-G glycoprotein, RVFV glycoprotein-dependent cell fusion could be prevented by treating target cells with trypsin, indicating
that one or more proteins (or protein-associated carbohydrate) on the host cell surface are needed to support membrane fusion. The cell–cell fusion
assay reported here will make it possible to study the membrane fusion activity of RVFV glycoproteins in a high-throughput format and to screen
small molecule inhibitors for the ability to block virus-specific membrane fusion.
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Rift Valley fever virus (RVFV) infects both humans and
many domesticated animals, causing acute fevers and, some-
times, retinal or hepatic complications with hemorrhagic
symptoms (Flick and Bouloy, 2005). Approximately 1–3% of
humans that become infected with RVFV die of the disease,
with case fatality proportions significantly higher for infected
animals. RVFV, which is spread by infected mosquitoes, was
first described in Kenya in 1931 and has since been documented
throughout much of Africa. In 2000, RVFV spread to the
Arabian peninsula, where it caused the first recorded outbreak
outside of the African continent (CDC, 2000a, 2000b).⁎ Corresponding authors. Fax: +1 215 573 2883.
E-mail addresses: doms@mail.med.upenn.edu (R.W. Doms),
aciarlet@mail.med.upenn.edu (A. Bertolotti-Ciarlet).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.07.035RVFV is a member of the genus Phlebovirus in the family
Bunyaviridae. Members of the Bunyaviridae family have a
single-stranded, tripartite RNA genome of negative polarity.
The medium RNA segment (M segment) encodes the viral
glycoproteins, GN and GC, and two non-structural proteins,
which are translated as a polyprotein precursor (Schmaljohn,
2001). The glycoproteins GN and GC are sufficient for RVFV
entry, which is predicted to employ a class II fusion mechanism
that is activated by low pH following endocytosis of the virion
(Garry and Garry, 2004; Ronka et al., 1995). The receptor(s) or
attachment factors for RVFV are unknown, although the virus
infects a wide range of cell types.
Study of the RVFV lifecycle is difficult due to the fact that
primary virus strains must be handled in BSL-3+/4 containment
facilities. The inherent difficulty of studying aspects of RVFV
under these conditions can be avoided if assays are developed
that allow for investigation of the viral proteins in a BSL-2
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glycoproteins GN and GC would make it possible to study the
structure and function of these proteins under BSL-2 conditions.
While fusion assays for members of the Bunyaviridae family
have been described, including La Crosse virus in the genus
Orthobunyavirus and Hantaan virus in the genus Hantavirus,
no fusion assay has been described for viruses in the genus
Phlebovirus (Arikawa et al., 1986; Jacoby et al., 1993; Ogino
et al., 2004; Plassmeyer et al., 2005; Pobjecky et al., 1986). One
of the difficulties in the development of a cell–cell fusion assay
for RVFV is that its glycoproteins are targeted to and retained in
the Golgi, where the virus buds. When expressed individually,
GN is targeted to the Golgi while GC is retained in the
endoplasmic reticulum (ER) (Gerrard and Nichol, 2002;
Wasmoen et al., 1988). Thus, GN is necessary for the proper
Golgi localization of GC during viral assembly.
To study the fusion activity of the RVFV glycoproteins, we
overexpressed GN and GC in hopes of saturating the Golgi
retention mechanisms that normally prevent efficient transport
to the cell surface. While plasmid vectors did not allow for
sufficiently high levels of expression to achieve this goal,
expression of the glycoproteins from an alphavirus replicon
vector led to readily detectable cell surface expression. WeFig. 1. Expression of RVFV glycoproteins from strain ZH501. (A–D) Detection of RV
RVFV polyclonal HMAF (red), anti-TGN46 (trans-Golgi network marker; green),
transfected cells: permeabilized (A) and non-permeabilized (B); VRP (VEE Replicon
Detection of RVFVGN and GC by immunoblot analysis using anti-RVFV polyclonal a
lysate, lane 3 shows pWRG7077-R4 transfected cell lysate, and lane 4 shows mock
Molecular markers are shown in kDa, arrows indicate position of GN and GC. (F) Su
transfected with pWRG7077-R4 or infected with VEE RVFVat MOI 5.0 or a control v
ice and analyzed on a FACScan 24 h post-infection/transfection. The channel with the
percentage of the maximum number of cells.found that brief low pH incubation of multiple cell types
expressing the RVFV glycoproteins on their surface resulted
in cell–cell fusion. Expression of the omega and alpha
subunits of β-galactosidase in the effector and target cells,
respectively, made it possible to quantify fusion by measuring
enzymatic activity of theα-complemented β-galactosidase
(Holland et al., 2004). Cell–cell fusion was induced when
cells were incubated at pH 6.2 or below, occurred over a
broad range of temperatures, and was dependent upon one or
more trypsin-sensitive proteins (or protein-associated carbo-
hydrate) on the surface of target cells. The development of a
high-throughput cell–cell fusion assay for RVFV will make it
possible to study the structure–function relationships of the
viral glycoproteins and to identify host cell factors needed to
support RVFV entry.
Results
Expression of RVFV glycoproteins on the cell surface
To study the membrane fusion activity of RVFV glycopro-
teins in the context of a cell–cell fusion assay, they must first be
transported from the Golgi to the cell surface. To achieve this,FV GN and GC by indirect immunofluorescence in HeLa cells, stained with anti-
and the nuclei stained with DAPI (blue). From left to right, pWRG7077-R4
Particle) RVFV infected cells: permeabilized (C) and non-permeabilized (D). (E)
ntibodies. Lane 1 shows RVFVVRP cell lysate, lane 2 shows VRP empty vector
transfected cell lysate. Lysates were from infected or transfected 293T/17 cells.
rface expression of RVFV GN and GC measured by FACS. 293T/17 cells were
ector as indicated. Cells were stained with anti-RVFVHMAF at 1:100 for 1 h on
highest number of cells for each sample is set to 100; the data are expressed as a
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of RVFV in HeLa cells either from the eukaryotic expression
vector pWRG7077-R4 (Spik et al., 2006) or from VEE or
Sindbis-like virus-based replicon vectors (Heise et al., 2003;
Thompson et al., 2006) and examined their localization by
indirect immunofluorescence microscopy. When the RVFV
glycoproteins were expressed from the plasmid vector, they
were targeted to the Golgi and were not expressed on the cell
surface at levels that could be detected, consistent with other
studies (Gerrard and Nichol, 2002; Wasmoen et al., 1988) (Figs.
1A and B). Since proteins that are retained in the Golgi can
sometimes be targeted to the cell surface upon overexpression
(Bos et al., 1993; Linstedt et al., 1997), we next examined the
localization of the RVFV glycoproteins when expressed from
the alphavirus vectors. When compared to expression via
pWRG7077, we found that both the VEE and Sindbis virus
vectors produced high levels of the RVFV glycoproteins as
judged by immunoblot analysis (Fig. 1E and data not shown),
though GN and GC were too close in size (55 kDa and 57 kDa,
respectively) to clearly resolve. In addition, both GN and GC
were detected on the surface of non-permeabilized cells when
expressed via the VEE vector (Figs. 1C and D). Similar results
were obtained with the Sindbis-like virus replicon, but because
the VEE replicon particles (VRP) could be produced to higher
titers, these were used in subsequent experiments.
To quantify the extent to which the RVFV glycoproteins
were delivered to the cell surface, 293T/17 cells were
transfected with pWRG7077-R4 or infected with VRPs,
both expressing strain ZH501 M segment. The next day, the
cells were stained with hyperimmune mouse ascitic fluid
prepared against RVFV and analyzed by flow cytometry. We
found that expression of the RVFV glycoproteins from the
pWRG7077-R4 plasmid resulted in low levels of surface
expression, while expression via the VRP resulted in much
higher levels of surface expression (Fig. 1F). Thus, over-
expression of the RVFV glycoproteins by an alphavirusFig. 2. Low pH-triggered syncytia formation of VEE replicon particle infected cells.
with either an empty VRP (vector 3014; expresses no glycoproteins) or a VRP expres
control empty vector are shown only for the Vero cells. After 24 h infection, the cells w
10% FBS for 2 h. The cells were then fixed with methanol, stained with Giemsa, anvector results in readily detectable surface expression, perhaps
as a result of saturating normal Golgi retention or retrieval
mechanisms.
RVFV cell–cell fusion using replicon vectors
Since alphavirus replicon vectors expressed RVFV glyco-
proteins on the surface of infected cells, they were utilized to
develop a cell–cell fusion assay. Members of the Bunyaviridae
family, including Phleboviruses, are pH-dependent (Gonzalez-
Scarano, 1985; Gonzalez-Scarano et al., 1984; Hacker and
Hardy, 1997; Jacoby et al., 1993; Ronka et al., 1995). Therefore,
24 h after infection with VRPs, we briefly incubated cells in a
low pH buffer to induce conformational changes in the
glycoproteins that might normally occur after endocytosis of
the virus. If the glycoproteins undergo the proper conforma-
tional changes, the membranes of two adjacent cells may fuse,
forming a syncytium. We found that several cell types formed
syncytia following expression of the RVFV glycoproteins and
brief treatment at pH 5.2, including 293T/17 cells, HeLa cells,
FLK cells, Huh-7 and HepG2 liver cells, CHO cells, and Vero
cells (Fig. 2 and data not shown). Syncytia formation was not
observed when cells were maintained at neutral pH nor was
fusion observed when cells infected with a control VRP
expressing no glycoproteins (vector 3014) were incubated at
either low or neutral pH (Fig. 2). Thus, cell–cell fusion was
dependent upon the presence of RVFV glycoproteins at the cell
surface as well as upon incubation at mildly acidic pH.
β-galactosidase α-complementation quantification of cell–cell
fusion
To more rigorously characterize the conditions under which
RVFV glycoprotein-mediated fusion occurred, we sought to
develop a quantitative cell–cell fusion assay based upon the
use of the VEE replicon system and activation of a reporterVero, Huh-7 (human hepatoma), or FLK (fetal lamb kidney) cells were infected
sing the RVFV glycoproteins as indicated in the figure. Results with the negative
ere treated with buffer at pH 7.4 or pH 5.2 for 1 min then incubated with DMEM
d photographs taken. Arrows indicate syncytia.
Fig. 3. β-galactosidase α-complementation quantification of cell–cell fusion.
293T/17 target cells transfected with pCMVαwere mixed with 293T/17 effector
cells transfected with pCMVω and either transfected with VSV-G or NiV
glycoprotein constructs or infected with VRPs expressing the RVFV
glycoproteins or no glycoproteins (empty vector). The cells were treated with
buffer at pH 5.2 or 7.4 for 10 min. Cells were then incubated 2.5 h with media at
37 °C, after which the cells were lysed and β-galactosidase activity measured.
Each experiment was completed in triplicate; each envelope was normalized to
100% at pH 5.2, with VRP empty vector normalized to RVFV fusion at pH 5.2.
Bars indicate standard error of the mean.
Fig. 4. pH and temperature dependence of RVFV glycoprotein induced cell–cell
fusion. 293T/17 target cells transfected with pCMVα were mixed with 293T/17
effector cells transfected with pCMVω and infected with either an empty VRP
vector or the VRP vector expressing the RVFV glycoproteins. In panel A, the
cells were treated with buffer at the specified pH for 10 min. The cells were then
incubated 2.5 h with media at 37 °C at pH 7.4, after which β-galactosidase
activity was measured. In panel B, the temperature dependence of cell–cell
fusion was determined by mixing the effector and target cells for 1 h at 37 °C,
then incubating them at the indicated temperature for an additional 10 min. The
cells were incubated at pH 5.2 for 10 min at the indicated temperature then
returned to pH 7.4 for 10 min, again at the indicated temperature. Cells were then
incubated at 37 °C for 2.5 h after which β-galactosidase activity was measured.
Each experiment was completed in triplicate; the fusion level was normalized to
RVFV fusion at pH 5.0. Bars indicate standard error of the mean.
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alphavirus replicons to inhibit host protein synthesis after
infection (Kaariainen and Ranki, 1984), multiple approaches
that relied upon the expression of a reporter gene subsequent to
cell–cell fusion failed. Therefore, we explored the use of the
β-galactosidase α-complementation-based fusion assay. In this
assay, the alpha subunit of β-galactosidase is expressed in one
cell population, while the omega subunit is expressed in
another. If fusion between the cell populations occurs after
they are mixed, the alpha and omega subunits (produced prior
to cell–cell fusion) assemble and functional β-galactosidase is
formed, the activity of which can be readily quantified
following cell lysis and addition of a chemiluminescent
substrate (Holland et al., 2004). By expressing the relatively
stable omega subunit in 293T/17 cells 24 h prior to infection
with an alphavirus replicon vector, we reasoned that sufficient
protein would remain following alphavirus-induced host–cell
protein synthesis shut-off such that fusion could still be
assayed.
The β-galactosidase α-complementation assay was used to
quantify fusion induced by several viral glycoproteins, includ-
ing those from RVFV, vesicular stomatitis virus (VSV, a pH-
dependent virus) (White et al., 1981), and Nipah virus (NiV, a
pH-independent virus) (Bossart et al., 2002; Tamin et al., 2002).
Target 293T/17 cells were transfected with pCMVα (Holland et
al., 2004) expressing the alpha subunit of β-galactosidase, while
293T/17 effector cells were transfected with pCMVω, expres-
sing the omega subunit of β-galactosidase. In addition, effector
cells were cotransfected with plasmids expressing either the
VSV or NiV glycoproteins. Alternatively, effector cells were
infected with VRPs expressing the RVFV glycoproteins or a
vector that did not express any glycoprotein 24 h after
transfection of the cells with the pCMVω plasmid. The effector
and target cells were mixed 48 h after transfection, allowed to
interact for 45–60 min, and then incubated for 10 min at theindicated pH (Fig. 3). Two and one-half hours later, the cells
were lysed and β-galactosidase activity measured.
We found that cells expressing the RVFV glycoproteins
fused at pH 5.2, with relative light units (RLU) of 60–100
typically being measured. In contrast, only background levels
(typically <10 light units) of β-galactosidase activity were
measured at pH 7.4. As expected, cells expressing the VSV-G
glycoprotein fused efficiently at acid pH (typically 100–
150 RLU), while cells expressing the NiV glycoproteins
fused at both pH 7.4 and pH 5.2 (typically 350–500 RLU).
Significant levels of β-galactosidase activity were not obtained
when cells infected with a VRP that did not express a viral
glycoprotein were used. We optimized the conditions needed
for RVFV glycoprotein-mediated membrane fusion by varying
the length of low-pH treatment and the length of time allowed
for syncytia formation/α-complementation. We determined that
RVFV fusion was optimal with low pH treatment incubation for
Fig. 5. RVFV dependent cell–cell fusion is sensitive to trypsin treatment of the target cells. 293T/17 target cells transfected with pCMVα were treated with trypsin for
15 min at 7 μg/μl (low) or 15 μg/μl (high) to cleave surface proteins. After inhibiting the trypsin with soybean trypsin inhibitor, the target cells were mixed with 293T/
17 effector cells transfected with pCMVω and either transfected with VSV-G or NiV glycoprotein constructs or infected with VRP vectors expressing the RVFV
glycoproteins or no glycoproteins (empty vector). The cells were treated with buffer at pH 5.2 or 7.4 for 10 min. Cells were then incubated 2.5 h with media at 37 °C pH
7.4, after which β-galactosidase activity was measured. Each experiment was completed in triplicate; each envelope was normalized to 100% at pH 5.2, with VRP
empty vector normalized to RVFV fusion at pH 5.2. Bars indicate standard error of the mean.
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2.5 h after acid treatment (data not shown).
pH and temperature dependence of RVFV
glycoprotein-mediated membrane fusion
To determine the pH threshold at which the RVFV
glycoproteins mediate membrane fusion, we used the
β-galactosidase complementation assay, incubating cells at pH
values ranging from pH 5.0 to pH 7.4 for 10 min, prior to a
2.5-hour incubation at neutral pH. The RVFV glycoproteins
began to induce cell–cell fusion at pH 6.2, with near maximal
fusion being attained at pH 5.0 (Fig. 4A). Fusion activity often
decreased below pH 5.0 (data not shown), perhaps due to
cytotoxic effects. An empty VRP did not induce fusion at any
pH value (Fig. 4A). Each experiment was completed in
triplicate, and all of the values were normalized to RVFV
induced fusion at pH 5.0. VSV-G was used as a positive control
and induced fusion at pH values of less than 6.4, consistent with
published results (White et al., 1981) (data not shown).
Since RVFV infects both mammals and mosquitoes, the
glycoproteins should induce cell–cell fusion over a range of
temperatures. To examine this, the β-galactosidase α-comple-
mentation fusion assay was used to quantify fusion at different
temperatures, from 4 °C to 37 °C (Fig. 4B). Cells were mixed
together at 37 °C for 1 h, and then incubated at the indicated
temperature for 10 min. The pH was then adjusted to pH 5.2 at
the specified temperature for 10 min, the media was neutralized,
and the cells returned to 37 °C 10 min later to ensure that the
efficiency of α-complementation at different temperatures was
not a consideration for interpretation of the fusion results. We
found that RVFV glycoproteins induced cell–cell fusion from
room temperature (24 °C) up to 37 °C, with increased fusion at
28 °C, 32 °C and 37 °C. When the experiment was performed at
42 °C, no quantifiable cell–cell fusion was observed (data not
shown). The data indicate that RVFV fused at lower
temperatures, although the glycoproteins functioned optimally
at temperatures from 28 to 37 °C.RVFV receptor characterization: trypsin inhibition
Although the receptor and/or attachment factors are not
known for RVFV, the cell–cell fusion assay can be used to begin
to understand the interactions between the glycoproteins and the
cellular receptor(s) for RVFV. To this end, target cells were
treated with trypsin, at 7 μg/μl or 15 μg/μl, to cleave proteins
from the target cell surface. RVFV glycoprotein-induced cell–
cell fusion was inhibited by trypsin treatment of the target cells,
indicating that the receptor(s) for RVFV is typsin-sensitive (Fig.
5). NiV was used as a positive control since ephrin-B2, the
receptor for NiV (Bonaparte et al., 2005; Negrete et al., 2005), is
a trypsin-sensitive protein (Bossart et al., 2001; Eaton et al.,
2004). As seen in Fig. 5, NiV glycoprotein-induced cell–cell
fusion was inhibited at both pH 5.2 and pH 7.4 by trypsin
treatment of the target cells. This effect was not the product of
nonspecific toxicity of the trypsin treatment because VSV-G-
induced cell–cell fusion was not affected, which agrees with
previously published reports that the VSV cellular receptor is
not protease sensitive (Schlegel et al., 1983) (Fig. 5). Thus, one
or more proteins (or protein-associated carbohydrate) on the
surface of target cells are needed for RVFV glycoprotein-
mediated membrane fusion to occur.
Discussion
Relatively little is known about the structure and function of
RVFV glycoproteins. While it is evident that GN and GC must
attach the virus to the cell surface and mediate membrane
fusion, little is known about their oligomeric structures, the
roles that GN and GC play in virus entry, or the mechanisms by
which antibodies neutralize RVFV. Likewise, the host cell
factors needed for RVFV entry are largely uncharacterized,
though the broad species and cell tropism of RVFV suggests
that it either interacts with a highly conserved receptor or can
bind to a variety of receptors or attachment factors.
The greatest stumbling block in developing a cell–cell fusion
assay for RVFV is that its glycoproteins, like those of other
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apparatus, where the virus buds (Gerrard and Nichol, 2002;
Kuismanen, 1984; Kuismanen et al., 1984; Schmaljohn, 2001;
Shi et al., 2004; Wasmoen et al., 1988). For a cell–cell fusion
assay to be developed, either the viral glycoproteins need to be
expressed on the cell surface or large amounts of virus need to
be added to the outside of cells to induce fusion-from-without.
Since we sought to develop an assay that would enable us to
manipulate the viral glycoproteins to test structural and
functional hypotheses, we investigated approaches that would
result in delivery of RVFV GN and GC to the cell surface.
Gerrard and Nichol have shown that, when coexpressed, both
GN and GC are delivered to the Golgi by virtue of a targeting
signal present within the transmembrane and cytoplasmic
domains of GN. Interestingly, some GN reached the cell surface
under their conditions, raising the possibility that the RVFV
glycoproteins are localized to the Golgi at least in part by a
retrieval mechanism from the cell surface (Gerrard and Nichol,
2002). If so, then overexpression of the glycoproteins could
alter the steady state distribution of GN and GC such that
sufficient levels are attained on the plasma membrane for the
induction of cell–cell fusion. Indeed, the distribution of several
cellular proteins that reside in the Golgi can be altered upon
overexpression, resulting in enhanced delivery to the cell
surface (Bos et al., 1993; Linstedt et al., 1997).
Expression of the RVFV GN and GC polyprotein from an
alphavirus vector resulted in readily detectable surface expres-
sion of these molecules. The alphavirus replicon technology can
be used to express a variety of proteins, including other viral
glycoproteins that are not naturally targeted to the cell surface
and are therefore difficult to manipulate in cell–cell fusion or
pseudovirion assays (Heise et al., 2003; Thompson et al., 2006).
Cells expressing the RVFV glycoproteins on the cell surface
formed syncytia when incubated at mildly acidic pH, suggesting
that this virus utilizes one or more endocytic pathways for
cellular infection, with endosomal pH playing a critical role in
inducing the fusion reaction. Othermembers of theBunyaviridae
family for which acid pH dependence has been shown include
La Crosse, Hantaan, and California encephalitis viruses
(Gonzalez-Scarano, 1985; Gonzalez-Scarano et al., 1984;
Hacker andHardy, 1997; Jacoby et al., 1993; Ronka et al., 1995).
Thus, the fact that RVFV glycoproteins induced cell–cell fusion
at low pH is not surprising. However, it remains to be
determined if RVFV needs other cellular factors in addition to
low pH for membrane fusion to occur. For example, the SARS
coronavirus (Simmons et al., 2005) and Ebola virus (Chandran
et al., 2005) envelope proteins require a low-pH dependent
endoproteolytic cleavage event in order for fusion to be elicited,
while the ASLV envelope protein must first bind to its specific
receptor, which triggers conformational changes in the envelope
protein that render it competent to elicit membrane fusion upon
subsequent exposure to low pH (Mothes et al., 2000). Since cell
surface RVFV glycoproteins were capable of eliciting efficient
cell–cell fusion, it is less likely that proteolytic activation of
either GN or GC is a required triggering event, though this
possibility cannot be ruled out. Whether binding to a specific
receptor might be needed prior to acid treatment is also notknown and cannot be addressed at present since the receptor(s)
for RVFV is unknown.
RVFV glycoprotein-induced fusion occurred over a broad
temperature range, as might be expected for a virus that
replicates in both mammalian and insect hosts. This correlates
with data from fusion-from-without assays using La Crosse
virus, which induces syncytia formation at temperatures above
25 °C (Pobjecky et al., 1986). Furthermore, the growth of many
members of the Bunyaviridae family, including Tahyna virus
(Danielova, 1975), is decreased at incubation at lower
temperatures in cell culture. Experiments examining the
susceptibility of Culex pipiens and Aedes fowleri mosquitoes
to RVFV determined that adult mosquitoes held at lower
temperatures (13–19 °C) were less susceptible to RVFV
infections, which correlates with our data indicating less
RVFV-induced fusion at lower temperatures (Brubaker and
Turell, 1998; Turell, 1989; Turell et al., 1985); however, there is
no evidence that fusion efficiency is the only factor in mosquito
susceptibility to RVFV infection.
Inhibition of RVFV induced cell–cell fusion was attempted
using neutralizing anti-RVFV sera; however, the antibodies
were unable to block cell–cell fusion. Several reports have
shown that some neutralizing anti-RVFV antibodies do not
block virus binding to the cell (Besselaar and Blackburn, 1992,
1994), a phenomenon also seen with Dugbe virus, a member of
the Nairovirus genus (Green et al., 1992). In the context of a
cell–cell fusion assay, the presence of antibodies may not
completely block the proximity of the overexpressed RVFV
glycoproteins to the target cell membrane. Therefore, when the
pH is lowered, conformational changes triggered in the
glycoproteins may still induce cell–cell fusion even when
antibodies are present. Furthermore, a large amount of antibody
was necessary for inhibition of the Hantaan virus cell–cell
fusion assay (Ogino et al., 2004), indicating inefficient
inhibition of cell–cell fusion. This phenomenon has also been
seen for other virus families; for example, higher concentrations
of entry inhibitors are necessary to block HIV cell–cell fusion
when compared to inhibition of infection (Reeves et al., 2005).
Because RVFV infects many cell types, with no known cell
refractory to RVFV infection, it is likely that the receptor for
RVFV is widespread or that there is no single receptor needed
for virus infection. As noted previously, some acid-dependent
viruses require specific receptors, whereas others can elicit
fusion with artificial membranes at low pH, thus demonstrating
that the presence of host cell proteins is not required (Corver et
al., 2000; White and Helenius, 1980). To further explore the
target cell requirements for RVFV glycoprotein-mediated
fusion, we treated target cells with trypsin and found that this
largely abolished RVFV-dependent membrane fusion, though it
did not affect fusion elicited by VSV-G. This indicates that a
host cell surface protein or protein-associated carbohydrate is
necessary for RVFV cell–cell fusion, and perhaps for virus
infection as well. Currently, we are in the process of analyzing a
more extensive panel of proteases for their effects on RVFV
fusion.
The fusion mechanism for members of the Bunyaviridae
family is not known, though modeling studies suggest that these
161C.M. Filone et al. / Virology 356 (2006) 155–164viruses employ a class II fusion mechanism, similar to members
of the Alphaviridae and Flaviviridae families (Garry and Garry,
2004; Tischler et al., 2005). While there is no specific
experimental evidence for this, the pH dependence of the
virus and the necessity for both GN and GC for fusion are
consistent with a class II fusion mechanism. The fusion assay
described here will allow further investigation of the structural
elements of GC necessary to induce cell–cell fusion. The
development of this quantitative cell–cell fusion assay will
make it possible to more fully explore the conditions needed for
RVFV-induced membrane fusion, to study the structure–
function relationships of the viral glycoproteins, and to screen
for small molecules that block RVFV entry or fusion that could
be used as antiviral drugs.
Materials and methods
Cell lines
Vero E6 (African green monkey kidney fibroblast (CV-1)),
HeLa (human, cervix carcinoma), U87 (human, glioblastoma–
astrocytoma), FLK (fetal lamb kidney), CHO (Chinese hamster
ovary), MDBK (Madin-Darby bovine kidney), PK13 (porcine
fibroblasts), BHK (baby hamster kidney), and 293T/17 (human
embryonic kidney) cells were maintained in Dulbecco's
Modified Eagle Medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA).
Plasmids and replicons
Venezuelan equine encephalitis (VEE) replicon particles
(VRP) with 3014 coat proteins and Girdwood (Sindbis-like)
replicon particle stocks expressing RVFV M segment, strain
ZH501, or empty VRP (3014 coat) were produced as previously
described (Heise et al., 2003; Thompson et al., 2006). Briefly,
full-length transcripts were derived from linearized plasmids
containing viral cDNA templates by using SP6- or T7-specific
mMessage Machine in vitro transcription kits (Ambion, Austin,
TX). Transcripts were electroporated into BHK-21 cells grown
in minimal essential medium (MEM; 10% fetal calf serum
[Gibco, Carlsbad, CA], 10% tryptose phosphate broth [Sigma,
Saint Louis, MO], and 0.29 mg of L-glutamine per ml
[Invitrogen, Carlsbad, CA]). Supernatants were harvested at
24–27 h post-electroporation, and 10% of the supernatant was
screened for the presence of replication competent virus using a
previously described cytopathic effect (CPE) assay (Heise et al.,
2003; Thompson et al., 2006). Supernatants that passed CPE
testing were considered safe for use under BSL-2 conditions
and were concentrated by pelleting through a 20% sucrose
cushion, resuspended in PBS, pH 7.4, frozen in 0.1-ml aliquots,
and replicon particles titrated on BHK-21 cells as previously
described (Heise et al., 2003; Thompson et al., 2006).
The RVFV plasmid pWRG7077-R4, a kind gift from Dr.
Connie Schmaljohn at United States Army Medical Research
Institute for Infectious Diseases (USAMRIID), expresses the
RVFVM segment from strain ZH501 beginning at the fourth in-
frame start codon. Therefore, it expresses GN and GC but doesnot encode the entire non-structural M segment proteins (Spik et
al., 2006). The codon-optimized NiV-F (pcNiV-Fopt, accession
no. AY816748) and NiV-G (pcNiV-Gopt, accession no.
AY816746), a kind gift from Dr. Benhur Lee at the University
of California, Los Angeles, were synthesized chemically and
subcloned into the pcDNA3.1 mammalian expression vector
(Levroney et al., 2005).
Expression of RVFV glycoproteins
To analyze the expression of RVFV glycoproteins in cells
infected with the alphavirus replicons, we performed immuno-
blots as previously described (Bertolotti-Ciarlet et al., 2005).
Briefly, 293T/17 cells were infected with VEE replicons
expressing the RVFV glycoproteins at a multiplicity of infection
(MOI) of 5 or transfected with pWRG7077-R4 using
Lipofectamine 2000 following manufacturer's instructions
(Invitrogen Corporation, Carlsbad, CA). At 24 h post-infection
or transfection, cell extracts were prepared in 50 mM Tris–HCl,
pH 7.4, 5 mM EDTA, 1% Triton X-100, and Complete protease
inhibitor cocktail (Roche Applied Sciences, Indianapolis, IN).
Cell lysates were incubated at 4 °C for 10 min and then
centrifuged at 10,000×g for 10 min. The supernatant was mixed
with sample buffer (0.08 M Tris–HCl, pH 6.8, 2% SDS, 10%
glycerol, 5% β-mercaptoethanol, 0.005% bromophenol blue)
and incubated at 95 °C for 3 min before electrophoresis in
Criterion 4–15% Tris–HCl sodium dodecyl sulfate polyacry-
lamide gel electrophoresis (SDS-PAGE) (Bio-Rad, Hercules,
CA). Immunoblot analysis was performed using rabbit poly-
clonal antibodies raised against RVFV peptides in both GN at
residue 374 (CFEHKGQYKGTMDSGQTKRE) and GC at
residue 976 (CFERGSLPQTRNDKTFAASK) (ProSci, Poway,
CA), and goat anti-rabbit horseradish peroxidase-conjugated
secondary antibody (Amersham Pharmacia, Buckinghamshire,
UK) followed by visualization with SuperSignal West Femto
Maximum Sensitivity Substrate (Pierce Biotechnology, Inc.,
Rockford, IL).
Localization and surface expression of RVFV glycoproteins
To visualize RVFV proteins on cells transfected with the
RVFVM segment, HeLa cells grown on 12 mm glass coverslips
(Fisher Scientific, Pittsburgh, PA) in 24 well plates were
transfected using Lipofectamine 2000 (Invitrogen Corporation,
Carlsbad, CA) following the manufacturer's instructions.
Twenty-four hours post-transfection, the cells were fixed
using 2% formaldehyde for 10 min at room temperature.
Cells were permeabilized with 0.5% TX-100 for 10 min. To
prevent nonspecific antibody binding, cells were then incubated
with phosphate buffered saline (PBS) containing 4% FBS for
30 min. The cells were incubated with hyperimmune mouse
ascitic fluid (HMAF) against RVFV (generous gift from Dr.
Mike Parker at USAMRIID) and sheep anti-TGN46 (Serotec
Inc., Raleigh, NC) Golgi antibody diluted 1:250 in PBS 4%
FBS for 1 h. A 1:500 dilution of an anti-mouse Alexa-594
secondary antibody (Invitrogen Corporation, Carlsbad, CA)
was used to detect theRVFVantibody, goat anti-sheepAlexa-488
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used to detect the Golgi, and the nuclei were stained with DAPI
(4′,6-Diamidino-2-phenylindole) at a 1:1000 dilution. The
coverslips were mounted onto slides using Fluoromount-G
(SouthernBiotech, Birmingham, AL).
To analyze cellular expression of RVFV glycoproteins
expressed from alphavirus replicons by indirect immunofluor-
escence, HeLa cells grown on 12 mm coverslips in a 24 well
plate were infected with a VEE replicon particle (VRP)
expressing RVFV glycoproteins (Collett et al., 1985) or an
empty VRP. The replicons were diluted to an MOI of 5 in 200 μl
PBS 1% FBS. After 1 h, 250 μl DMEM 10% FBS was added to
each well, and the cells were incubated for 24 h at 37 °C. Cells
were fixed and stained as described for transfected cells.
Immunofluorescent images were taken on a Nikon E600
microscope at 60× magnification utilizing UV illumination.
To analyze surface expression ofRVFVglycoproteins by flow
cytometry, 293T/17 cells were transfected with pWRG7077-R4
RVFVM segment ZH501 using Lipofectamine 2000 or infected
with the VRP expressing RVFVM segment ZH501 at a MOI of
5 for 24 h. Cells were then surface stained with anti-RVFV
mouse HMAF for 1 h on ice then stained with anti-mouse
secondary antibody conjugated to phycoerythrin (PE) for
30 min on ice. The cells were analyzed on a FACScan (Becton
Dickinson, Franklin Lakes, NJ) and evaluated using FlowJo
software (TreeStar, Inc., Ashland, OR).
RVFV syncytia formation fusion assay
Cells infected with Girdwood (Sindbis-like) or VEE
alphavirus replicon particles encoding RVFV M segment strain
ZH501, as described above, were treated with 100 μl Earle's
salt solution 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid) and 20 mM MES (2-Morpholinoetha-
nesulfonic acid) at the specified pH for 1 to 10 min at 37 °C 24 h
post-infection. 500 μl DMEM 10% FBS was then added, and
the cells were incubated for 1–2 h at 37 °C. Cells were then
fixed with methanol on ice for 5–7 min and allowed to dry
before treatment for 15 min with Giemsa stain (Sigma, Saint
Louis, MO) diluted 1:10 in water at room temperature. Images
were captured using a Nikon Eclipse TE300 microscope at
40× magnification.
RVFV β-galactosidase α-complementation quantification
To quantify the fusion activity of RVFV glycoproteins, we
used the β-galactosidase fusion assay as described by Holland
et al. using 293T/17 cells. β-galactosidase α-complementation
is based on the fact that the β-galactosidase enzyme is a dimer;
the dimerization domain (the alpha subunit) can be separated
from the rest of the protein (the omega subunit). Target cells
were transfected with pCMVα (Holland et al., 2004) expressing
the alpha subunit of β-galactosidase, while the effector cells
were transfected with pCMVω, expressing the omega subunit
of β-galactosidase. As a positive control for pH-dependent
fusion, vesicular stomatitis virus glycoprotein (VSV-G) expres-
sing cells were used; 7 μg pBlueScript-VSV-G was cotrans-fected with 7 μg pCMVω into effector cells. As a positive
control for pH-independent fusion, Nipah virus (NiV) codon
optimized F and G protein expressing cells were used; 3.5 μg
pcDNA3.1 NiV F, 3.5 μg pcDNA3.1 NiV G, and 7 μg pCMVω
were cotransfected into effector cells. For RVFV glycoprotein
expressing cells, 293T/17 cells were transfected with 7 μg
pCMVω using Lipofectamine 2000. Twenty-four hours post-
transfection, the pCMVω transfected cells were infected with
VRPs expressing RVFV glycoproteins from the ZH501 M
segment or with empty 3014 VRP, as described above. Twenty-
four hours post-transfection, all cells were treated with 500 mM
sodium butyrate to boost expression of proteins from the pCMV
vectors.
Forty-eight hours post-transfection, the cells were resus-
pended in DMEM, and 2.5×105 cells of targets and effectors
were combined (Holland et al., 2004). The mixed cells were
incubated for 30 to 60 min to allow for effector and target cell
binding. Then, cells were gently spun down at 800–900 rpm for
2 min, the supernatant removed and the cells treated with 100 μl
of Earle's salt solution with 20 mM HEPES and 20 mM MES
from pH 5.0 to 7.4 for 5–10 min at 37 °C to induce pH-
dependent conformational changes in glycoproteins and allow
for cell–cell fusion. The pH was neutralized by adding 500 μl
DMEM 10% FBS with 10 mM HEPES, and the cells then
incubated at 37 °C for 2.5 to 4 h to allow for syncytia formation
and α-complementation. To monitor the extent of fusion, the
cells were spun down, lysed using Galacto-Star lysis buffer, and
read following the Galacto-Star directions (Applied Biosys-
tems, Foster City, CA). Each experiment was completed in
triplicate. At least three individual experiments were normalized
to 100% at low pH, and then the normalized values were
averaged together.
Temperature dependence of RVFV-mediated membrane fusion
To analyze the effect of different temperatures on the fusion
activity of RVFV glycoproteins, the fusion assay described
above was utilized with several modifications. The pCMVα
transfected target cells and RVFV glycoprotein expressing
effector cells were combined at 37 °C and incubated for 1 h to
allow for cell–cell binding. The cells were pelleted at 800–
900 rpm for 2 min, and the supernatant aspirated. Then, 100 μl
of buffer at the desired pH and specified temperature, from 4 °C
to 37 °C, was added for 10 min. As described above, DMEM
10% FBS with 10 mM HEPES was added to normalize the pH
and the cells were incubated at the specified temperatures for an
additional 10 min. The cells were then incubated at 37 °C for
2.5 h to enable β-galactosidase complementation to occur under
identical conditions regardless of the temperature at which the
cells were incubated at acid pH.
Fusion inhibition by trypsin
To analyze the effect of trypsin treatment on RVFV
glycoprotein fusion activity, pCMVα transfected target cells
were suspended in DMEM then treated with 7 or 15 μg/μl of
trypsin (L-1-tosylamido-2-phenylethyl chloromethyl ketone)
163C.M. Filone et al. / Virology 356 (2006) 155–164(Sigma, St. Louis, MO) for 15 min at 37 °C. Soybean trypsin
inhibitor (50 μg/μl; Sigma, St. Louis, MO) was then added and
incubated for 30 min at 37 °C to inactivate the trypsin,
preventing cleavage of proteins on the effector cells. The targets
and effectors were then combined for 45 min, and the fusion
assay completed and results analyzed as described above.
Acknowledgments
We would like to thank Benhur Lee (UCLA) for supplying
the codon optimized NiV plasmids, Connie Schmaljohn
(USAMRIID) for supplying the RVFV M segment plasmids,
Mike Parker (USAMRIID) for the anti-RVFV HMAF, Martha
Collier, Nancy Davis, and Robert Johnston (UNC-CH) for
packaging the VEE replicon particles, Kenya Madric (UNC-
CH) for packaging the Sindbis-like replicon particles, and
Nathaniel Landau (The Salk Institute for Biological Studies) for
the β-galactosidase α-complementation plasmids.
This work was supported by NIH grants from the Middle
Atlantic Regional Center for Excellence in Biodefense and
Emerging Infectious Diseases (U54 AI 057168), T32 AI
055400, and by a Developmental Award from the Southeastern
Regional Center for Excellence in Biodefense and Emerging
infectious diseases (SERCEB; U54 AI057157) to MTH.
References
Arikawa, J., Takashima, I., Hashimoto, N., Takahashi, K., Yagi, K., Hattori, K.,
1986. Epidemiological studies of hemorrhagic fever with renal syndrome
(HFRS) related virus infection among urban rats in Hokkaido, Japan. Arch.
Virol. 88 (3–4), 231–240.
Bertolotti-Ciarlet, A., Smith, J., Strecker, K., Paragas, J., Altamura, L.A.,
McFalls, J.M., Frias-Staheli, N., Garcia-Sastre, A., Schmaljohn, C.S., Doms,
R.W., 2005. Cellular localization and antigenic characterization of crimean-
congo hemorrhagic fever virus glycoproteins. J. Virol. 79 (10), 6152–6161.
Besselaar, T.G., Blackburn, N.K., 1992. The synergistic neutralization of Rift
Valley fever virus by monoclonal antibodies to the envelope glycoproteins.
Arch. Virol. 125 (1–4), 239–250.
Besselaar, T.G., Blackburn, N.K., 1994. The effect of neutralizing monoclonal
antibodies on early events in Rift Valley fever virus infectivity. Res. Virol.
145 (1), 13–19.
Bonaparte, M.I., Dimitrov, A.S., Bossart, K.N., Crameri, G., Mungall, B.A.,
Bishop, K.A., Choudhry, V., Dimitrov, D.S., Wang, L.F., Eaton, B.T.,
Broder, C.C., 2005. Ephrin-B2 ligand is a functional receptor for
Hendra virus and Nipah virus. Proc. Natl. Acad. Sci. U.S.A. 102 (30),
10652–10657.
Bos, K., Wraight, C., Stanley, K.K., 1993. TGN38 is maintained in the trans-
Golgi network by a tyrosine-containing motif in the cytoplasmic domain.
EMBO J. 12 (5), 2219–2228.
Bossart, K.N., Wang, L.F., Eaton, B.T., Broder, C.C., 2001. Functional
expression and membrane fusion tropism of the envelope glycoproteins of
Hendra virus. Virology 290 (1), 121–135.
Bossart, K.N., Wang, L.F., Flora, M.N., Chua, K.B., Lam, S.K., Eaton, B.T.,
Broder, C.C., 2002. Membrane fusion tropism and heterotypic functional
activities of the Nipah virus and Hendra virus envelope glycoproteins.
J. Virol. 76 (22), 11186–11198.
Brubaker, J.F., Turell, M.J., 1998. Effect of environmental temperature on the
susceptibility of Culex pipiens (Diptera: Culicidae) to Rift Valley fever
virus. J. Med. Entomol. 35 (6), 918–921.
CDC, 2000a. Outbreak of Rift Valley Fever—Saudi Arabia, August–November
2000. Morb. Mort. Wkly. Rep. 49, 905–908.
CDC, 2000b. Outbreak of Rift Valley Fever—Yemen, August–October 2000.
Morb. Mort. Wkly Rep. 49, 1065–1066.Chandran, K., Sullivan, N.J., Felbor, U., Whelan, S.P., Cunningham, J.M., 2005.
Endosomal proteolysis of the Ebola virus glycoprotein is necessary for
infection. Science 308 (5728), 1643–1645.
Collett, M.S., Purchio, A.F., Keegan, K., Frazier, S., Hays, W., Anderson, D.K.,
Parker, M.D., Schmaljohn, C., Schmidt, J., Dalrymple, J.M., 1985.
Complete nucleotide sequence of the M RNA segment of Rift Valley
fever virus. Virology 144 (1), 228–245.
Corver, J., Ortiz, A., Allison, S.L., Schalich, J., Heinz, F.X., Wilschut, J., 2000.
Membrane fusion activity of tick-borne encephalitis virus and recombinant
subviral particles in a liposomal model system. Virology 269 (1), 37–46.
Danielova, V., 1975. Growth of Tahyna virus at low temperatures. Acta Virol. 19
(4), 327–332.
Eaton, B.T., Wright, P.J., Wang, L.F., Sergeyev, O., Michalski, W.P., Bossart, K.N.,
Broder, C.C., 2004. Henipaviruses: recent observations on regulation of trans-
cription and the nature of the cell receptor. Arch. Virol., Suppl. (18), 122–131.
Flick, R., Bouloy, M., 2005. Rift Valley fever virus. Curr. Mol. Med. 5 (8),
827–834.
Garry, C.E., Garry, R.F., 2004. Proteomics computational analyses suggest that
the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion
protein (beta-penetrenes). Theor. Biol. Med. Model 1 (1), 10.
Gerrard, S.R., Nichol, S.T., 2002. Characterization of the Golgi retentionmotif of
Rift Valley fever virus G(N) glycoprotein. J. Virol. 76 (23), 12200–12210.
Gonzalez-Scarano, F., 1985. La Crosse virus G1 glycoprotein undergoes a
conformational change at the pH of fusion. Virology 140 (2), 209–216.
Gonzalez-Scarano, F., Pobjecky, N., Nathanson, N., 1984. La Crosse bunyavirus
can mediate pH-dependent fusion from without. Virology 132 (1), 222–225.
Green, E.M., Armstrong, S.J., Dimmock, N.J., 1992. Mechanisms of
neutralization of a nairovirus (Dugbe virus) by polyclonal IgG and IgM.
J. Gen. Virol. 73 (Pt 8), 1995–2001.
Hacker, J.K., Hardy, J.L., 1997. Adsorptive endocytosis of California
encephalitis virus into mosquito and mammalian cells: a role for G1.
Virology 235 (1), 40–47.
Heise, M.T., White, L.J., Simpson, D.A., Leonard, C., Bernard, K.A., Meeker,
R.B., Johnston, R.E., 2003. An attenuating mutation in nsP1 of the Sindbis-
group virus S.A.AR86 accelerates nonstructural protein processing and up-
regulates viral 26S RNA synthesis. J. Virol. 77 (2), 1149–1156.
Holland, A.U., Munk, C., Lucero, G.R., Nguyen, L.D., Landau, N.R., 2004.
Alpha-complementation assay for HIV envelope glycoprotein-mediated
fusion. Virology 319 (2), 343–352.
Jacoby, D.R., Cooke, C., Prabakaran, I., Boland, J., Nathanson, N., Gonzalez-
Scarano, F., 1993. Expression of the La Crosse M segment proteins in a
recombinant vaccinia expression system mediates pH-dependent cellular
fusion. Virology 193 (2), 993–996.
Kaariainen, L., Ranki, M., 1984. Inhibition of cell functions by RNA–virus
infections. Annu. Rev. Microbiol. 38, 91–109.
Kuismanen, E., 1984. Posttranslational processing of Uukuniemi virus
glycoproteins G1 and G2. J. Virol. 51 (3), 806–812.
Kuismanen, E., Bang, B., Hurme, M., Pettersson, R.F., 1984. Uukuniemi virus
maturation: immunofluorescence microscopy with monoclonal glycopro-
tein-specific antibodies. J. Virol. 51 (1), 137–146.
Levroney, E.L., Aguilar, H.C., Fulcher, J.A., Kohatsu, L., Pace, K.E., Pang, M.,
Gurney, K.B., Baum, L.G., Lee, B., 2005. Novel innate immune functions
for galectin-1: galectin-1 inhibits cell fusion by Nipah virus envelope
glycoproteins and augments dendritic cell secretion of proinflammatory
cytokines. J. Immunol. 175 (1), 413–420.
Linstedt, A.D., Mehta, A., Suhan, J., Reggio, H., Hauri, H.P., 1997. Sequence
and overexpression of GPP130/GIMPc: evidence for saturable pH-sensitive
targeting of a type II early Golgi membrane protein. Mol. Biol. Cell 8 (6),
1073–1087.
Mothes, W., Boerger, A.L., Narayan, S., Cunningham, J.M., Young, J.A., 2000.
Retroviral entry mediated by receptor priming and low pH triggering of an
envelope glycoprotein. Cell 103 (4), 679–689.
Negrete, O.A., Levroney, E.L., Aguilar, H.C., Bertolotti-Ciarlet, A., Nazarian,
R., Tajyar, S., Lee, B., 2005. EphrinB2 is the entry receptor for Nipah virus,
an emergent deadly paramyxovirus. Nature 436 (7049), 401–405.
Ogino, M., Yoshimatsu, K., Ebihara, H., Araki, K., Lee, B.H., Okumura, M.,
Arikawa, J., 2004. Cell fusion activities of Hantaan virus envelope
glycoproteins. J. Virol. 78 (19), 10776–10782.
164 C.M. Filone et al. / Virology 356 (2006) 155–164Plassmeyer, M.L., Soldan, S.S., Stachelek, K.M., Martin-Garcia, J., Gonzalez-
Scarano, F., 2005. California serogroup Gc (G1) glycoprotein is the principal
determinant of pH-dependent cell fusion and entry. Virology 338 (1),
121–132.
Pobjecky, N., Smith, J., Gonzalez-Scarano, F., 1986. Biological studies of the
fusion function of California serogroup Bunyaviruses. Microb. Pathog.
1 (5), 491–501.
Reeves, J.D., Lee, F.H., Miamidian, J.L., Jabara, C.B., Juntilla, M.M., Doms,
R.W., 2005. Enfuvirtide resistance mutations: impact on human
immunodeficiency virus envelope function, entry inhibitor sensitivity,
and virus neutralization. J. Virol. 79 (8), 4991–4999.
Ronka, H., Hilden, P., Von Bonsdorff, C.H., Kuismanen, E., 1995. Homodimeric
association of the spike glycoproteins G1 and G2 of Uukuniemi virus.
Virology 211 (1), 241–250.
Schlegel, R., Tralka, T.S., Willingham, M.C., Pastan, I., 1983. Inhibition of VSV
binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-
binding site? Cell 32 (2), 639–646.
Schmaljohn, C.a.J.W.H., 2001. Bunyaviridae: the viruses and their replication,
In: Knipe, P.M.H.D.M., Griffin, D.E., Martin, M.A., Lamb, R.A., Roizman,
B., Straus, S.E. (Eds.), Fields Virology, 4th ed. Lippincott, Williams and
Wilkins, Philadelphia, PA.
Shi, X., Lappin, D.F., Elliott, R.M., 2004. Mapping the Golgi targeting and
retention signal of Bunyamwera virus glycoproteins. J. Virol. 78 (19),
10793–10802.
Simmons, G., Gosalia, D.N., Rennekamp, A.J., Reeves, J.D., Diamond, S.L.,
Bates, P., 2005. Inhibitors of cathepsin L prevent severe acute respiratory
syndrome coronavirus entry. Proc. Natl. Acad. Sci. U.S.A. 102 (33),
11876–11881.Spik, K., Shurtleff, A., McElroy, A.K., Guttieri, M.C., Hooper, J.W.,
Schmaljohn, C., 2006. Immunogenicity of combination DNA vaccines for
Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and
Crimean Congo hemorrhagic fever virus. Vaccine 24 (21), 4657–4666.
Tamin, A., Harcourt, B.H., Ksiazek, T.G., Rollin, P.E., Bellini, W.J., Rota, P.A.,
2002. Functional properties of the fusion and attachment glycoproteins of
Nipah virus. Virology 296 (1), 190–200.
Thompson, J.M., Whitmore, A.C., Konopka, J.L., Collier, M.L., Richmond,
E.M., Davis, N.L., Staats, H.F., Johnston, R.E., 2006. Mucosal and
systemic adjuvant activity of alphavirus replicon particles. Proc. Natl.
Acad. Sci. U.S.A. 103 (10), 3722–3727.
Tischler, N.D., Gonzalez, A., Perez-Acle, T., Rosemblatt, M., Valenzuela, P.D.,
2005. Hantavirus Gc glycoprotein: evidence for a class II fusion protein.
J. Gen. Virol. 86 (Pt 11), 2937–2947.
Turell, M.J., 1989. Effect of environmental temperature on the vector
competence of Aedes fowleri for Rift Valley fever virus. Res. Virol. 140
(2), 147–154.
Turell, M.J., Rossi, C.A., Bailey, C.L., 1985. Effect of extrinsic incubation
temperature on the ability of Aedes taeniorhynchus and Culex pipiens to
transmit Rift Valley fever virus. Am. J. Trop. Med. Hyg. 34 (6), 1211–1218.
Wasmoen, T.L., Kakach, L.T., Collett, M.S., 1988. Rift Valley fever virus M
segment: cellular localization of M segment-encoded proteins. Virology 166
(1), 275–280.
White, J., Helenius, A., 1980. pH-dependent fusion between the Semliki Forest
virus membrane and liposomes. Proc. Natl. Acad. Sci. U.S.A. 77 (6),
3273–3277.
White, J., Matlin, K., Helenius, A., 1981. Cell fusion by Semliki Forest,
influenza, and vesicular stomatitis viruses. J. Cell Biol. 89 (3), 674–679.
